Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study.
D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008223:Lymphoma / Q000188:drug therapy*; D008453:Maytansine / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D010078:Oxazines / Q000633:toxicity*
D010078:Oxazines; D008453:Maytansine